Derek J. Maetzold sells 1,622 shares of Castle Biosciences, Inc. (NASDAQ:CSTL)

(NASDAQ:CSTL – GET FREE REPORT) Insider Derek J. Maetzold sold 1,622 shares of the company’s stock in a transaction on Wednesday, August 30th. The shares were sold at an average price of $20.03, for a total value of $32,488.66. After completing the sale, the insider now owns 119,905 shares in the company, valued at $2,401,697.15. The sale was disclosed on file with the Securities and Exchange Commission, and is available through the Securities and Exchange Commission’s website.

Castle Biosciences stock performance

CSTL traded down $0.27 during midday trade on Friday, to reach $19.66. The company’s trading volume amounted to 119,827 shares, compared to an average trading volume of 416,133 shares. Castle Biosciences, Inc. The twelve-month low is at $9.26 and the twelve-month high is at $30.08. The company’s market capitalization is $527.08 million, the P/E ratio is -5.87, and the beta is 0.84. The company’s 50-day SMA is $16.85, and the 200-day SMA is $20.10.

Castle Biosciences (NASDAQ:CSTL – GET FREE REPORT) released its latest quarterly earnings results on Wednesday, August 2nd. The company reported earnings per share ($0.70) for the quarter, beating the consensus analyst estimate of ($1.01) by $0.31. Castle Biosciences had a negative net margin of 53.04% and a negative return on equity of 22.57%. The company generated $50.14 million in revenue for the quarter, compared to analyst estimates of $43.51 million. As a group, sell-side analysts expect Castle Biosciences, Inc. Posting -3.75 earnings per share for the current fiscal year.

Institutional investors influence Castle Biosciences

A number of institutional investors and hedge funds have recently made changes to their positions in the CSTL. Nisa Investment Advisors LLC boosted its holdings in Castle Biosciences by 561.0% in the first quarter. Nisa Investment Advisors LLC now owns 1,084 shares of the company’s stock valued at $25,000 after acquiring an additional 920 shares during the most recent quarter. Ten Capital Wealth Advisors LLC acquired a new position at Castle Biosciences during the fourth quarter valued at approximately $32,000. Assetmark Inc. increased its stake in Castle Biosciences by 215.8% in the fourth quarter. Assetmark Inc. Now 1,500 shares of the company’s stock are worth $35,000 after purchasing an additional 1,025 shares during the last quarter. Royal Bank of Canada boosted its position in Castle Biosciences shares by 40.5% during the second quarter. Royal Bank of Canada now owns 2,880 shares of the company’s stock worth $39,000 after purchasing an additional 830 shares during this period. Finally, Tower Research Capital LLC TRC increased its stake in Castle Biosciences by 61.2% during the third quarter. Tower Research Capital LLC TRC now owns 1,821 shares of the company’s stock valued at $47,000 after purchasing an additional 691 shares during the most recent quarter. Institutional investors own 85.75% of the company’s shares.

Analyst promotions and downgrades

Several equity research analysts have recently commented on the stock. Lake Street Capital lowered its target price on shares of Castle Biosciences from $41.00 to $32.00 in a research note on Monday, June 5th. BTIG Research lowered its target price on shares of Castle Biosciences from $38.00 to $30.00 in a research report on Thursday, June 15th. SVB Securities lowered its target price target for Castle Biosciences shares from $50.00 to $35.00 in a report on Monday, June 5th. Robert W. Baird raised target price for shares of Castle Biosciences from $25.00 to $30.00 in a research note on Thursday, August 3rd. Finally, Scotiabank cut its price target on Castle Biosciences from $54.00 to $33.00 in a research report on Wednesday, June 7th.

View our latest research report on Castle Biosciences

About Citadel Biosciences

(Get a free report)

Castle Biosciences, Inc., a commercial-phase diagnostics company, is focused on providing diagnostic and prognostic testing services for skin cancers. Its flagship product is DecisionDx-Melanoma, a multiplex Gene Expression Profile (GEP) test to determine the risk of metastasis for patients diagnosed with invasive cutaneous melanoma.

Featured stories

Insider buying and selling quarterly for Castle Biosciences (NASDAQ:CSTL)

This instant news alert was created by MarketBeat’s narrative science and financial data technology to provide readers with the fastest and most accurate reporting. This story was reviewed by the MarketBeat editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

Before you consider Castle Biosciences, you’ll want to hear this.

MarketBeat tracks Wall Street’s top-rated and best-performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market joins in… Castle Biosciences was not on the list.

While Castle Biosciences currently has a “buy” rating among analysts, the higher-rated analysts believe these five stocks are better buys.

View the five stocks here

A beginner's guide to investing in stocks

Click the link below and we’ll send you MarketBeat’s guide to investing in venture stocks and which betting firms show the most promise.

Get this free report

(tags for translation)Castle Biosciences

You may also like...

Leave a Reply

Your email address will not be published. Required fields are marked *